REGN•benzinga•
Analyst Ratings for Regeneron Pharmaceuticals
Summary
Within the last quarter, Regeneron Pharmaceuticals (NASDAQ:REGN) has observed the following analyst ratings:
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on September 9, 2022 by benzinga